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Introduction:  In ES-SCLC  patients  with  residual  intrathoracic  disease  after  ﬁrst-line  chemotherapy,  the
addition  of  thoracic  radiotherapy  reduces  the  risk  of  intrathoracic  recurrence,  and improves  2-year
survival.  To identify  patient  subgroups  for future  trials  investigating  higher  dose  (extra)thoracic  radio-
therapy,  we investigated  the  prognostic  importance  of  number  and  sites  of metastases  in  patients
included  in  the  CREST  trial.
Materials/  methods:  Additional  data  on sites  and  numbers  of metastases  were  collected  from  individual
records  of 260  patients  from  the  top  9 recruiting  centers  in  the randomized  CREST  trial  (53%  of 495 study
patients),  which  compared  thoracic  radiotherapy  (TRT)  to  no  TRT  in  ES-SCLC  patients  after  any  response
to  chemotherapy.  All  patients  received  prophylactic  cranial  irradiation.
Results:  The  clinical  characteristics  and  outcomes  of  the  260  patients  analyzed  here did not  differ  signif-
icantly  from  that  of the  other  235  patients  included  in the  CREST  trial,  except  that fewer  patients  had  a
WHO  = 0  performance  status  (24%  vs  45%),  and  a  higher  proportion  had WHO  =  2  (15%  vs  5%;  p  < 0.0001).
No  distant  metastases  were  recorded  in  5%, 39%  had  metastases  conﬁned  to one  organ,  34% to  two,  and
22%  to three  or  more  organ  sites.  Metastases  were  present  in  the  liver  (47%),  bone  (40%),  lung  (28%),
extrathoracic  (non-supraclavicular)  lymph  nodes  (19%),  supraclavicular  nodes  (18%),  adrenals  (17%)  and
other sites  (12%).  The  OS  (p =  0.02)  and  PFS  (p = 0.04)  were  signiﬁcantly  better  in  patients  with  2  or  fewer
metastases,  with  OS  signiﬁcantly  worse  if liver  (p  =  0.03)  and/or  bone  metastases  (p  = 0.04)  were present.
Discussion:  This  analysis  of patients  recruited  from  the  top  9  accruing  centers  in  the  CREST  trial  suggests
that  future  studies  evaluating  more  intensive  thoracic  and  extra-thoracic  radiotherapy  in  ES-SCLC  should
focus on patients  with  fewer  than  3 distant  metastases.
©  2017  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC  BY∗ Corresponding author at: Department of Radiation Oncology, VU University
edical center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
E-mail address: bj.slotman@vumc.nl (B.J. Slotman).
ttp://dx.doi.org/10.1016/j.lungcan.2017.03.007
169-5002/© 2017 The Author(s). Published by Elsevier Ireland Ltd. This is an open acceslicense  (http://creativecommons.org/licenses/by/4.0/).
1. IntroductionMost patients with extensive stage small cell lung cancer
(ES-SCLC) have persistent intrathoracic tumor after completing
chemotherapy, and will experience intrathoracic failure as the ﬁrst
site of progression [1]. In the CREST trial, we demonstrated that
s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Patient characteristics of selected from top accruing centers and non-selected patients.
selected patients non-selected patients signiﬁcance
(n  = 260) (n = 235)
Age median (years) 63 63 NS
Sex  Male 136 (52.3%) 135 (57.4%) NS
Female 124 (47.7%) 100 (42.6%)
WHO  performance score 0 62 (23.8%) 105 (44.7%) p < 0.0001
1  179 (68.8%) 118 (50.2%)
2  71 (27.3%) 12 (5.1%)
Response CR 10 (3.8%) 16 (6.8%) NS
PR  179 (68.8%) 170 (72.3%)
‘Good response’ 71 (27.3%) 49 (20.9%)
Intrathoracic disease No 28 (10.8%) 34 (14.5%) NS
Yes  232 (89.2%) 201 (85.5%)
Interval diagnosis to start
of chemotherapy median (days) 3 3 NS
Interval start chemotherapy
 
 
a
r
[
s
T
c
d
i
e
a
r
4
a
r
(
t
c
t
w
[
f
T
Oto randomization median (days) 96
Interval last chemotherapy
to radiotherapy median (days) 31
 relatively low dose of thoracic radiotherapy (TRT) was able to
educe the risk of intrathoracic progression from nearly 80–44%
2]. Furthermore, thoracic radiotherapy was associated with a non-
igniﬁcant beneﬁt in overall survival at 1 year (33 vs. 27%; p = 0.066).
he difference in overall survival at 2 years was statistically signiﬁ-
ant (13% vs 3%; p = 0.004), although the study was  not powered to
etect a survival difference at this landmark. A stratiﬁcation factor
n the CREST trial was presence or absence of intrathoracic dis-
ase after chemotherapy, and a subsequent analysis demonstrated
 statistically signiﬁcant overall survival beneﬁt in patients with
esidual intrathoracic disease after chemotherapy [3,4].
As the risk of intrathoracic disease progression after TRT was
4%, and as side-effects of TRT were minimal in the CREST trial,
 higher TRT dose merits consideration. The predominant sites of
elapse in patients receiving both prophylactic cranial irradiation
PCI) and TRT within the CREST trial, was outside the brain and
horax [2], and radiotherapy to extra-thoracic metastases has been
onsidered as well. A study exploring the latter was closed prema-
urely due to toxicity and futility, and although a signiﬁcant beneﬁt
as seen in local control, no beneﬁt in overall survival was  observed
5].
In order to identify patient groups that are most likely to beneﬁt
rom inclusion into future studies evaluating aggressive radiother-
able 2
verall survival and progression-free survival.
Overall s
(HR; 95%
n  n (%)
Ipsiateral lung No 202
Yes  58 (22.3%) 1.18 (0.8
Contralateral lung No 244
Yes  16 (6.2%) 1.04 (0.6
Supraclavicular nodes No 214
Yes  46 (17.7%) 0.81 (0.5
Extrathoracic
(non-supraclavicular)
lymph nodes
No 210
Yes  50 (19.2%) 1.00 (0.7
Adrenal glands No 216
Yes  44 (16.9%) 0.72 (0.5
Liver  No 139
Yes  121 (46.5%) 1.34 (1.0
Bone  No 157
Yes  103 (39.6%) 1.33 (1.0
Other sites No 229
Yes  31 (11.9%) 0.84 (0.5100 NS
34 NS
apy strategies, we studied the prognostic importance of metastatic
load (numbers, sites).
2. Materials/methods
The CREST study was  a phase 3 randomized controlled trial
which enrolled 495 patients from 42 hospitals, mainly in the
Netherlands and the United Kingdom. Eligible patients had to be
18 years or older, have WHO  performance status 0–2, ES-SCLC, any
response after 4–6 cycles of platinum-based chemotherapy with-
out evidence of disease progression at any site [2]. Patients with
brain, leptomeningeal or pleural metastases were excluded from
the trial. Patients were randomized to receive PCI with TRT (30 Gy
in 10 fractions) or PCI only.
Due to limited funding for data management, it was decided to
limit this study to the top 9 of the 42 recruiting centers in the CREST
trial (7 Dutch and 2 UK centers) which had accrued a total of 260
patients (53% of 495 study patients). We  obtained ethics and IRB
approval to collect the additional data. and analyzed the individual
patient records for details on anatomical location and numbers of
distant metastases.
Characteristics of the 260 patients included in this analysis were
compared with the 235 CREST patients who were not selected. Dif-
ferences in progression-free survival (PFS) and overall survival (OS)
urvival Progression-free survival
 CI) Signiﬁcance (HR; 95% CI) p-value
p = 0.29 p = 0.77
7–1.59) 0.96 (0.71–1.28)
p = 0.89 p = 0.99
2–1.71) 0.99 (0.60–1.65)
p = 0.23 p = 0.97
8–1.14) 1.01 (0.73–1.37)
p = 0.98 p = 0.93
3–1.39) 0.96 (0.72–1.34)
p = 0.06 p = 0.89
1–1.02) 0.98 (0.70–1.36)
p = 0.03 p = 0.06
3–1.73) 1.27 (0.99–1.63)
p = 0.04 p = 0.01
2–1.73) 1.39 (1.08–1.79)
p = 0.39 p = 0.46
6–1.26) 0.86 (0.59–1.27)
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Fig. 1. Overall survival of patients with and without liver metastases (a), with an
without bone metastases (b), and 0–2 versus 3 or more metastases (c).52 B.J. Slotman et al. / Lung
or patients with and without metastases in ipsilateral lung, con-
ralateral lung, supraclavicular lymph nodes, distant lymph nodes
i.e. outside thorax and supraclavicular fossa), adrenal glands, liver,
one, and other sites were compared using the log-rank test and
ox proportional hazard analysis was used to calculate hazard
atios with 95% conﬁdence intervals. A separate analysis of the
ffect of TRT was only performed for liver metastases and bone
etastases in this additional study because of the small number of
atients in the other subgroups.
. Results
The characteristics of the patients are provided in Table 1. Their
edian age was 63 years and 52% were male. At randomization, 4%
f patients had a CR after chemotherapy, 69% a PR and 27% a ‘good
esponse’. Details on response evaluation have been described pre-
iously [2]. Patients were classiﬁed as having a ‘good response’ if
heir tumor regressed, but less than was required to qualify for a
R according to RECIST criteria, or if not all sites of initial disease
ould be evaluated according to RECIST criteria after completion of
hemotherapy. Residual intrathoracic disease post-chemotherapy
as identiﬁed in 89% of patients. The clinical characteristics of the
60 patients analyzed were not signiﬁcantly different from the 235
ther patients in the CREST trial, with the exception that fewer
atients had a World Health Organization (WHO) performance sta-
us = 0 (24% vs 45%) and a higher proportion were WHO  = 2 (15% vs
%; overall: p < 0.0001). Patients in the analysis had a similar PFS
3.5 months), but a trend towards inferior OS, when compared to
he non-selected patients (median 7.4 vs 8.1 months; p = 0.06).
No distant metastases were recorded in 13 patients (5.0%), in
hom the diagnosis of ES-SCLC was based only on the extent of the
ntrathoracic tumor. In 59 patients (22.7%), there were 1–2 metas-
ases and 188 patients (72.3%) had 3 or more metastases. In 102
atients (39.2%), the metastases were conﬁned to one organ, in 88
33.8%) to two, and in 57 (21.9%) to three or more organs. The pre-
ominant sites of metastasis were the liver (46.5%), bone (39.6%),
ung (28.5%), distant lymph nodes (19.2%), supraclavicular nodes
17.7%), and adrenal glands (16.9%) [Table 2].
Progression-free survival was superior in the absence of bone
etastases (p = 0.01), and showed a favorable trend in the absence
f liver metastases (p = 0.06). Overall survival (OS) was signiﬁcantly
orse if liver metastases (Fig. 1a; p = 0.03) were present. Patients
ith bone metastases also had signiﬁcantly worse OS (Fig. 1b;
 = 0.04). For other metastatic sites, no differences in PFS or OS were
bserved.
Regardless of the administration of TRT, both OS
HR 1.43 (95%CI = 1.07-1.92); p = 0.02) and PFS (HR = 1.35
95%CI = 1.02–1.78); p = 0.04) were signiﬁcantly better in patients
ith up to 2 metastases, compared to those with 3 or more distant
etastases (Fig. 1c). Survival of patients with 0, compared to 1 or
o 2 distant metastases did not differ signiﬁcantly.
Univariate analysis revealed no signiﬁcant differences in PFS
etween patients diagnosed with liver metastases who received
n = 69) and not received TRT (n = 52; Table 3). In patients with-
ut liver metastases, those receiving TRT (n = 63) had signiﬁcantly
onger PFS compared to those who did not receive TRT (n = 52;
R = 1.74′ p = 0.001).
In patients with bone metastases, PFS was signiﬁcantly longer
n patients receiving TRT (n = 50) than in to those who did not
n = 53; HR 1.60; p = 0.02). In patients without bone metastases, the
ifference in PFS did not reach statistical signiﬁcance (HR = 1.36;
 = 0.06).
In patients with 0–2 distant metastases, TRT led to a statistically
igniﬁcant beneﬁt in PFS (n = 61; HR = 2.02; p = 0.003). In patients
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Table  3
Effect of thoracic radiotherapy and site and number of metastases.
Progression free survival Overall survival
HR (95% CI); p-value HR (95% CI); p-value
Liver metastases
present 1.22 (0.75–1.76) 0.90 (0.62–1.31)
p  = 0.28 p = 0.57
absent 1.74 (1.23–2.46) 1.38 (0.96–1.98)
p  = 0.001 p = 0.08
Bone metastases
present 1.60 (1.08–2.38) 0.94 (0.63–1.41)
p  = 0.02 p = 0.76
absent 1.36 (0.98–1.87) 1.19 (0.85–1.65)
p  = 0.06 p = 0.32
Number of metastases
0−2 2.02 (1.24–3.28) 1.55 (0.93–2.58)
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eighth edition of the TNM classiﬁcation of lung cancer, J. Thor. Oncol. 10 (2015)
1515–1522.
[7] A.G. Nicholson, K. Chansky, J. Crowley, et al., Revision of the clinical andp  = 0.003 p = 0.09
>  2 1.25 (0.93–1.66) 0.94 (0.70–1.27)
p  = 0.14 p = 0.69
ith more than 2 distant metastases, the difference in PFS was
tatistically signiﬁcant (HR1.25; p = 0.14).
The differences in OS between patients without liver metastases
ho received and not received TRT was not statistically signiﬁ-
ant (HR = 1.38; p = 0.08), probably due to small numbers. Only for
atients with 2 or fewer distant metastases, there was a trend for
mproved OS (HR = 1.55; p = 0.09)
In a multivariate analysis of PFS, including WHO  Perfor-
ance status (0,1,2), TRT (yes/no), liver metastases (yes/no), bone
etastases (yes/no), and number of metastases (0–2 vs >2),
he following factors were statistically signiﬁcant: TRT (HR = 1.48
95%CI = 1.15-1.91); p = 0.002) and absence of bone metastases
HR = 1.36 (95%CI = 1.04-1.78); p = 0.02). A multivariate analysis for
S did not identify signiﬁcant factors associated with survival.
. Discussion
This secondary analysis of patients recruited from the top 9
enters accruing to the CREST trial suggests that future studies eval-
ating more intensive thoracic and extrathoracic radiotherapy in
S-SCLC could focus on patients with a low burden of disease.
These inclusion criteria are almost identical to those of the
hase II randomized trial on consolidative extra-cranial radiother-
py which was closed recently (NRG-RTOG0937). In this study, all
esponding patients were randomized between PCI plus consol-
dative radiotherapy to the thorax and 1–4 other extra-cranial sites
f disease, or PCI only. The primary endpoint was overall survival
nd the accrual target was 154 patients. The study was  closed early
fter an interim analysis of 86 patients who were entered over a
 year period. The results have been presented in abstract form
nly [5], and reveal an imbalance between the study groups, with
ore adverse prognostic factors (advanced age, worse performance
tatus, fewer CR, and more metastases) in the experimental arm,
lthough only the difference in age reached statistical signiﬁcance.er 108 (2017) 150–153 153
The use of TRT and radiotherapy to extra-thoracic sites was associ-
ated with signiﬁcantly longer progression-free survival. However,
no signiﬁcant difference in overall survival was observed. The risk
of intrathoracic recurrence was reduced from 83 to 26%, and recur-
rence rates in treated metastases decreased from 78 to 42% [5]. In
the experimental arm more toxicity was observed, including one
death due to lung toxicity.
One of the limitations of the present study is that data was  col-
lected only from the top-accruing centers. However, we believe that
the observed imbalance between treatment arms compared to the
full CREST dataset, probably did not inﬂuence our conclusions. In
addition, the smaller numbers of patients in certain subgroups (e.g.
metastatic sites), make statistical comparisons difﬁcult. For exam-
ple, the beneﬁcial effect of TRT observed in patients with bone
metastases could be attributable to the lower frequency of liver
metastases in this subgroup, with total numbers being too small
to address this question adequately. The new UICC staging for lung
cancer proposes a subdivision into a single metastasis in one organ
versus multiple metastases in one or more organs [6,7]. We did
not observe a difference between patients with 0–1 versus to 2
metastatic sites, a ﬁnding that could reﬂect small patient numbers.
The signiﬁcant reduction in the risk of metastases in the brain
[1], thorax [2,5] and extra-thoracic disease sites [5] demonstrates
that radiotherapy is effective in ES-SCLC and this might translate
into improved OS in patients with a limited disease load. Our ﬁnd-
ings suggest that future studies should focus on patients with less
than 3 metastases.
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